8-K: BioAtla Secures $40M for Key Cancer Drug Development

BioAtla forms a new subsidiary and secures $40 million from Inversagen AI to advance its Ozuriftamab Vedotin (Oz-V) cancer therapeutic into a Phase 3 clinical trial for oropharyngeal squamous cell carcinoma.

Summary

• BioAtla, Inc. entered into an Investment Agreement with Inversagen AI, LLC and Alliance International Resources Corp. on December 30, 2025.
• BioAtla formed BA 3021 SPV LLC (the SPV), a wholly-owned subsidiary, to which it will grant an exclusive, worldwide, perpetual, and irrevocable license for its Ozuriftamab Vedotin (Oz-V) intellectual property rights for human uses (excluding certain senescent cell elimination therapies).
• Inversagen AI will acquire an aggregate 35% common unit ownership in the SPV for $40 million through a private placement.
• BioAtla will retain 65% ownership of Oz-V across all solid tumor indications after the transaction.
• The $40 million gross proceeds are earmarked for general operating expenses and clinical trial expenses to advance Oz-V into a Phase 3 Study for 2L+ oropharyngeal squamous cell carcinoma (OPSCC).
• The transaction is structured in two closings: an initial $5 million for 4.375% of SPV units by January 30, 2026, and a subsequent $35 million for an additional 30.625% of SPV units by March 31, 2026, contingent on Inversagen AI's financing.
• Inversagen AI, LLC is a new company formed by Inversagen, LLC (which holds a license to BioAtla's CAB senescence technologies) and GATC Health Corp.

Sentiment

Score: 8

Explanation: The filing announces a significant funding injection ($40 million) for a key clinical asset (Oz-V) to advance into a pivotal Phase 3 trial, while BioAtla retains majority ownership (65%). This substantially de-risks the development of Oz-V and provides capital for general operations and clinical expenses. The FDA Fast Track designation and large potential market opportunity for Oz-V are strong positives. The main caveat is the related-party nature of the transaction and the contingency of the second tranche on Inversagen AI's financing.

Positives

• Secured $40 million in funding specifically for advancing Oz-V into a Phase 3 study, reducing immediate financial burden on BioAtla.
• Retains 65% ownership of Oz-V across all solid tumor indications, allowing BioAtla to benefit significantly from future success.
• The funding enables the initiation of a pivotal Phase 3 trial for Oz-V in 2L+ OPSCC, with potential for accelerated approval.
• Oz-V has FDA Fast Track Designation for recurrent or metastatic SCCHN, which includes OPSCC.
• The transaction structure is described as maximizing equity value for shareholders.
• Potential to expand Oz-V application to all HPV+ cancers, representing a significant market opportunity of over $7 billion worldwide.
• BioAtla has secured a partnership with an unnamed commercial manufacturer for Oz-V supply, supporting cost-effective development and commercialization.
• The partnership with GATC Health and Inversagen AI also opens avenues for collaboration on CAB senolytic therapies, with BioAtla maintaining cancer therapeutic rights.

Negatives

• BioAtla is selling a 35% ownership stake in its Oz-V asset, which means sharing future profits from this specific asset.
• The second closing of $35 million is contingent on Inversagen AI completing its own financing of at least $35 million, introducing a contingency risk.
• The transaction involves related parties, as BioAtla's Chairman and CEO, Dr. Jay Short, and his spouse serve as managers of Inversagen, LLC and Inversagen AI, which could raise corporate governance questions or perceived conflicts of interest.

Risks

• Ability to continue as a going concern and need for additional funding for CAB technology platform and product candidates.
• Preliminary or interim clinical results may not be indicative of results from later cohorts or larger populations.
• Potential delays in clinical and preclinical trials.
• Uncertainties inherent in research and development, including meeting anticipated clinical endpoints, commencement/completion dates for trials, regulatory submission/approval dates, and possibility of unfavorable new clinical data.
• Whether regulatory authorities will be satisfied with clinical study design and results or take favorable regulatory actions.
• Dependence on the success of the CAB technology platform.
• Ability to enroll patients in ongoing and future clinical trials.
• Successful selection and prioritization of assets for development.
• Ability to form and succeed in collaborations and partnerships with third parties.
• Reliance on third parties for manufacturing and supply of product candidates for clinical trials.
• Reliance on third parties to conduct clinical trials and some aspects of research/preclinical testing.
• Potential adverse impacts due to geopolitical or macroeconomic events, including health epidemics or pandemics.

Future Outlook

BioAtla expects to use the $40 million proceeds to advance Oz-V into a Phase 3 Study for 2L+ OPSCC, with enrollment anticipated to begin in early 2026. The company sees a clear registrational path with potential for accelerated approval in the US. Discussions are ongoing with potential partners to expand Oz-V's opportunity into HPV-positive solid tumors, including cervical cancer, which represents a market opportunity exceeding $7 billion worldwide. The partnership with GATC Health and Inversagen AI also lays a foundation for advancing CAB senolytic therapies for age-related diseases, with BioAtla retaining cancer therapeutic rights.

Management Comments

• "We are excited to announce this partnership for advancing Oz-V into Phase 3 development for the treatment of patients with OPSCC under this creative, single-asset financing structure which maximizes our equity value for our shareholders." Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc.
• "As we previously announced, we have a clear registrational path with the potential for accelerated approval in the US and are moving to initiate the Phase 3 pivotal trial, which we anticipate will begin enrollment in early 2026." Jay M. Short, Ph.D.
• "In addition, we continue to advance discussions with potential partners to expand the opportunity more broadly with Oz-V into HPV-positive solid tumors, including cervical cancer." Jay M. Short, Ph.D.
• "ROR2 is an attractive therapeutic target as it functions at the crossroads of cancer, senescence, and inflammation." Ian Jenkins, Chief Scientific Officer at GATC Health.
• "This is an important partnership for us as it provides a near-term commercial opportunity in OPSCC, as well as laying the foundation to advance the mission of Inversagen AI to cure age-related diseases." Jayson Uffens, Chief Technology Officer at GATC Health.
• "Enabling the selective removal of inflamed, pathogenic senescent cells positions us at the forefront of advances in the treatment of longevity and age-related disease." Jayson Uffens.

Industry Context

This transaction highlights a growing trend in the biotechnology sector where companies leverage special purpose vehicles (SPVs) and strategic partnerships to de-risk and fund specific high-potential assets, especially in costly late-stage clinical development. The focus on Oz-V, an antibody-drug conjugate (ADC) targeting ROR2, aligns with the increasing interest in targeted therapies for oncology. Furthermore, the involvement of GATC Health, an AI-driven company, and the explicit mention of senescence and longevity technologies, reflects the convergence of AI, oncology, and age-related disease research, a significant area of innovation in the broader biotech and pharmaceutical industry. The potential expansion into HPV+ cancers also positions Oz-V within a substantial and underserved market segment.

Comparison to Industry Standards

• The use of an SPV for single-asset financing is a recognized strategy in biotech to fund specific programs while retaining broader corporate control and potentially maximizing equity value, similar to how other smaller biotechs might spin out assets or form joint ventures to share development costs and risks for late-stage programs.
• Oz-V's FDA Fast Track Designation for SCCHN is a positive indicator, aligning with regulatory efforts to accelerate promising therapies for serious conditions, comparable to other innovative oncology drugs receiving similar designations.
• The estimated market opportunity of over $7 billion for HPV+ cancers positions Oz-V in a competitive but large market, comparable to other blockbuster oncology drugs targeting specific cancer types with high unmet needs.
• The collaboration with an AI company (GATC Health) for senescence and longevity technologies reflects a broader industry trend of integrating AI and machine learning into drug discovery and development, aiming to improve efficiency and identify novel targets, similar to partnerships seen with larger pharmaceutical companies and AI startups.

Corporate Governance

Related Party Transactions

• The Investment Agreement is with Inversagen AI, LLC, which is deemed a related party.
• BioAtla's Chairman and Chief Executive Officer, Dr. Jay Short, and his spouse serve as managers of Inversagen, LLC and Inversagen AI, LLC.
• BioAtla previously entered into an exclusive license agreement with Inversagen, LLC in 2019 (amended July 2020) for CAB-antibodies in inflammatory diseases associated with aging, outside of cancer, in return for low-single digit royalty payments.

Stakeholder Impact

• Shareholders: Potential for increased equity value due to non-dilutive financing for a key asset, reduced financial risk for Oz-V development, and potential for accelerated approval and commercialization. However, 35% ownership of Oz-V is ceded.
• Employees: Continued employment and potential growth opportunities related to the advancement of Oz-V and new research collaborations.
• Customers (Patients): Potential for a new treatment option for 2L+ OPSCC and potentially other HPV+ cancers, especially given the FDA Fast Track Designation.
• Creditors: Improved financial stability for BioAtla due to the $40 million capital injection, potentially reducing short-term liquidity concerns.

Next Steps

• Initial Closing of the SPV transaction, where BioAtla receives $5 million, expected by January 30, 2026.
• Initiation of the Phase 3 pivotal trial for Oz-V in 2L+ OPSCC, with enrollment anticipated to begin early 2026.
• Second Closing of the SPV transaction, where BioAtla receives $35 million, expected no later than March 31, 2026, subject to Inversagen AI's financing.
• BioAtla will lead Phase 3 trial execution for Oz-V in OPSCC through data readout for potential accelerated approval.
• Continue advancing discussions with potential partners to expand Oz-V opportunity into HPV-positive solid tumors, including cervical cancer.
• Collaboration with Inversagen AI for research and development of CAB senolytic therapies.
• Filing of the full Investment Agreement as exhibits to BioAtla's Annual Report on Form 10-K for the year ending December 31, 2025.

Key Dates

Recommendation

The $40 million financing significantly de-risks the development of Oz-V, a promising oncology asset with FDA Fast Track Designation and a clear path to a pivotal Phase 3 trial. BioAtla retains 65% ownership, allowing substantial upside participation. The strategic partnership also opens doors for future collaborations in the high-growth area of senescence and AI-driven drug discovery. While the related-party nature requires scrutiny, the overall financial and clinical advancement is a strong positive catalyst for the company's valuation and future prospects.

Keywords

BioAtla, Ozuriftamab Vedotin, Oz-V, CAB-ROR2-ADC, Oropharyngeal Squamous Cell Carcinoma, OPSCC, Phase 3, Clinical Trial, Biotechnology, Oncology, ADC, Antibody Drug Conjugate, ROR2, Senescence, GATC Health, Inversagen AI, Special Purpose Vehicle, SPV, Private Placement, Cancer Therapy, HPV+ Cancers, Fast Track Designation, Drug Development, Financial Agreement